A paper by Drummond et al. (2023) examines how well being know-how evaluation our bodies take care of the problem of worth evaluation for cell and gene therapies (also called Superior Remedy Medicinal Merchandise (ATMPs) in Europe). To do that the authors:
…undertook i) a focused assessment of the literature on the medical and financial proof wants for these therapies, and ii) an in-depth evaluation of HTA stories from 8 main jurisdictions for 9 cell and gene therapies in 10 indications, along with any related publicly accessible paperwork on managed entry agreements and post-launch proof necessities.
The authors used an information extraction kind from Drummond et al. (2019).
The authors look at these components and decide the share of which these components had been cited in a optimistic, detrimental or impartial method.
Additionally of curiosity is that whereas some broader or societal worth components had been cited in ATMP worth evaluation, this was removed from ubiquitous.
The paper is attention-grabbing all through and you’ll learn the total paper right here.
